Overall, we have demonstrated that TIM-1 is a viable marker for IL-10+ Bregs in humans and that TIM-1+ B cells are decreased in frequency and have an impaired regulatory function in patients with SSc. This evidence concerns the gene IL10 and systemic sclerosis.